Clinical Trial Update: Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab [Phase 3]

View source ↗

Summary

Extension study update for secukinumab prefilled syringes in adults with moderate to severe chronic plaque-type psoriasis completing preceding Phase III studies…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-12-20